ICIs and ICI‐based combination therapies have significantly improved clinical outcomes in patients with ccRCC.[6] However, this benefit is limited to small subsets of ccRCC patients, most of whom acquire drug resistance even if they have high levels of immune checkpoint molecule expression (e.g., PD‐L1).[31] This situation poses considerable challenges for ccRCC immunotherapy. Here, CD274 is linked to nonpapillary renal cell carcinoma.